• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Sun Pharmaceutical Industries Ltd.
    07 Jul 2025
    1610.50
    0.53%
    Sun Pharma says working towards full regulatory resolution at 3 plants facing USFDA action
    Business Line
    The company is facing an import alert for the Halol facility and also is in receipt of non-compliance letter for the Mohali facility
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Solara Active Pharma Sciences Ltd.
    06 Jul 2025
    675.45
    -0.56%
    Solara Active Pharma Sciences: A Strategic Shift Towards High-Value Growth
    Solara Active Pharma Sciences: A Strategic Shift Towards High-Value Growth
    NDTV Profit
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 4.31% of shares in last quarter. Total pledge stands at 38.95% of promoter holdings
    logo
    Emcure Pharmaceuticals Ltd.
    04 Jul 2025
    1360.40
    0.52%
    Emcure Pharmaceuticals Bulk Deal: BC Investments Offloads Stake For Rs 563 Crore
    Emcure Pharmaceuticals Bulk Deal: BC Investments Offloads Stake For Rs 563 Crore
    NDTV Profit
    The public shareholder sold the 2.37% stake for Rs 1,250.44 apiece.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. has gained 46.64% in the last 6 Months
    Emcure Pharma shares dip after 2.4% stake change hands in block trades
    Business Standard | 04 Jul 2025 1 more
    Emcure Pharma Block Deal: Public Shareholder BC Investments To Sell 2.4% Stake
    NDTV Profit | 03 Jul 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    04 Jul 2025
    1610.50
    0.53%
    Price pressures to intensify for drugmakers, says Sun Pharmaceutical
    Business Standard
    Sun Pharma expects global pricing strain due to policy shifts, as FY25 US sales rise 5.8% despite compliance challenges; specialty business lifts overall growth
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 30 day SMA of 1608.8
    logo
    Lupin Ltd.
    04 Jul 2025
    2051.80
    0.28%
    Lupin launches nasal spray in US, part of 200-drug pipeline by FY30
    Business Standard
    The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. has an average target of 2326.00 from 8 brokers.
    Lupin launches generic Ipratropium Bromide nasal spray in US market
    Business Line | 04 Jul 2025
    logo
    Aurobindo Pharma Ltd.
    04 Jul 2025
    1091.60
    -0.77%
    Buy Or Sell: Aurobindo Pharma, LIC Housing Finance On Ajit Mishra's Radar Check Target Price
    Buy Or Sell: Aurobindo Pharma, LIC Housing Finance On Ajit Mishra's Radar Check Target Price
    NDTV Profit
    The stock recommendations carry specific stop loss and target price.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1090.5
    logo
    Cipla Ltd.
    04 Jul 2025
    1559.00
    0.69%
    Cipla faces revenue and margin pressure ahead of Revlimid patent expiry
    Cipla faces revenue and margin pressure ahead of Revlimid patent expiry
    Economic Times
    Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Margin is expected to drop significantly in FY26 and FY27, with concerns about finding a suitable buyer after Torrent's acquisition of JB Chemicals. While Cipla is pursuing new respiratory and complex generic assets, analysts doubt these will fully offset Revlimid's decline.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above all available SMAs
    logo
    Piramal Pharma Ltd.
    03 Jul 2025
    205.63
    0.95%
    Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
    Business Standard
    Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth 3,523 crore
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr
    logo
    Sigachi Industries Ltd.
    03 Jul 2025
    43.95
    0.21%
    Sigachi Mishap: Expert panel begins investigation
    Business Line
    The blast occurredon June 30 morning when 143 workers were on duty in the plant of the drug-maker
    Copy LinkShare onShare on Share on Share on
    Sigachi Industries Ltd. is trading at high day volume of 129.3M.
    logo
    Biocon Ltd.
    03 Jul 2025
    360.20
    0.54%
    Karnataka CM's remark on Covid vaccines 'factually incorrect': Biocon chief
    Business Standard
    Biocon founder Kiran Mazumdar-Shaw on Thursday opposed Karnataka Chief Minister Siddaramaiah's remarks linking covid-19 vaccines with a spate of heart attack deaths in the state's Hassan district, saying such claims are "'factually incorrect" and "misleading". Siddaramaiah has suggested that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' approved. In a social media post, Shaw said "covid-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation." "These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their...
    Copy LinkShare onShare on Share on Share on
    Mutual Funds have increased holdings from 8.77% to 15.24% in Jun 2025 qtr.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • L T Elevator
    • TechD Cybersecurity
    • Euro Pratik Sales
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd